Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Advair's Labeling Variation Stems From Permissible Design Differences, US FDA Says

Executive Summary

Patient instructions for use of Mylan’s fluticasone/salmeterol generic are noticeably different from GSK’s reference listed drug but fall within the ‘different manufacturers’ exception to the ‘same labeling’ requirement.

Advertisement

Related Content

US FDA Again Looks Outside Generic Drugs Office For New Director
Combination Products: US FDA Aims For Limited Two-Application Solutions
Mylan’s Generic Advair Approval Showcases US FDA Efforts To Boost Complex Products
Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Advair Bioequivalence Guidance Falls Short of GSK’s Requests

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel